Novartis Vaccine Bexsero Approved in Australia
August 15, 2013 at 05:59 AM EDT
Novartis (NYSE: NVS ) announced today that the Australian Therapeutic Goods Administration (TGA) has added Bexsero®, a multi-component Meningococcal B (MenB) vaccine (recombinant, adsorbed) suspension for injection 0.5 ml pre-filled syringe, to the Australian Register of Therapeutic Goods (ARTG) for use in individuals from two months of age and
